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Abstract:  CART peptides are endogenous neurotransmitters that are involved in a variety of physiologic functions.   
Injection of CART 55-102 into the nucleus accumbens produces no effect, but when co-administered with cocaine, it  
reduces the locomotor and rewarding properties of cocaine. In a human study, subjects carrying a missense mutation  
of the CART gene exhibited increased anxiety and depression. Also, several animal studies support the idea that CART is 
involved in anxiety and depression, and they also suggest several possible mechanisms by which this may occur. Thus, 
there is interesting evidence that CART peptides play a role in anxiety and depression, and that CART peptides may be 
endogenous antidepressants. 
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INTRODUCTION 
  CART (cocaine and amphetamine regulated transcript) 
peptides are peptide neurotransmitters and neurohormones 
involved in the effects of psychostimulants as well as in 
other functions [1-3]. CART peptides appear to attenuate the 
actions of psychostimulants at several sites in the brain. For 
example, they blunt the locomotor actions of cocaine and 
amphetamine and also the rewarding and reinforcing proper-
ties of cocaine when injected into the nucleus accumbens [4-
7].  
  In the last several years, new data suggests that CART 
peptides (CART 55-102 and 62-102) may have antidepres-
sant properties, and some aspects of this are especially   
intriguing. An interesting case involves an Italian family that 
has been identified with a missense mutation in the CART gene 
which results in missorted and improperly processed CART 
peptide [8, 9]. The striking phenotype of family members 
carrying the mutation is early onset obesity. These findings 
have contributed substantially to our understanding of the 
role of CART peptides in feeding, and of the processing of 
these peptides. Moreover, the availability of this family of-
fers a unique opportunity to explore other roles of CART 
peptides in humans. Accordingly, several family members 
underwent psychological testing. 
  The test utilized was developed by Italian psychologists 
for Italian children and adolescents, and evaluates levels of 
depression, anxiety and eating disorders [10] (also see [11] 
for details). From the family of interest, only three family 
members with the mutation took the test, and two family 
members without the mutation were tested. The control 
populations were much larger. The family members carrying 
the mutation (M) scored high on the anxiety and depression  
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scales, in comparison to members of the family without   
the mutation (NM), a large normal group (C), or a group of 
obese children from the same clinic but without the mutation 
(Ob) (Fig. 1). Their anxiety and depression scores were   
similar to the scores of other anxious and depressed patients 
(P), and it is known that anxiety and depression can co-
occur. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Anxiety and Depression scores among family members, 
both with and without the mutation, and other groups. C shows the 
scores for the control (normal) group (n = 188 for the depression 
control group, and n = 210 for the anxiety control group). P repre-
sents the pathological subjects (n = 20 for depression, and n = 35 
for anxiety). Ob indicates obese children from the same clinic but 
without the mutation and from other families (n = 30 in both cases). 
M indicates scores for family members carrying the mutation   
(n = 3), and NM shows data from the family members without   
the mutation (n = 2). See text for details and results of ANOVA 
analysis. Reproduced from [11]. 
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  Among the anxiety scores (Fig. 1), C was different from 
M, Ob and P (P<0.001). Also, P was different from Ob 
(P<0.001), and Ob was different from M (P<0.01). Impor-
tantly, M was different from NM (P<0.05). Thus, the M 
group, or the family members carrying the mutation, was 
different from all groups except the P (pathological) group. 
Among the depression scores, C was different from P and M 
(P<0.001) and from Ob (P<0.01) as well. P was different 
from Ob (P<0.001) and NM (P<0.01). Ob was also different 
from M (P<0.001), and importantly, M was different from 
NM (P<0.01).  
  While the obese patients from the same clinic (Ob) had 
scores significantly higher compared to normals (C), the 
scores from the M group were even higher compared to the 
Ob group. This suggests that the obese phenotype by itself is 
not the sole determinant of the high scores. However, it must 
be kept in mind that these data reflect very small numbers of 
subjects for both the NM (n = 2) and N (n = 3) groups. The 
other family members did not participate, and there are no 
other known groups of humans with this or a similar muta-
tion. Thus, a cautious interpretation is needed, and further 
studies of CART and depression are warranted. Also, in this 
human study, it is not known if the anxiety and depression 
effects are a direct or indirect result of the mutation. 
IS THE CART PEPTIDE AN ENDOGENOUS ANTI-
DEPRESSANT? 
  Given these findings in humans, it is interesting that   
several studies in animals have provided supportive results. 
CART peptides are found in brain regions and tissues   
involved in depression, anxiety and stress [3, 12-14]. There 
is data showing that CART mRNA is down regulated in   
the frontal cortex of rats subjected to chronic mild stress:   
an animal model of depression [15]. Several tests with   
rodents including elevated plus maze, social interaction, and 
startle suggest a role for CART peptides in anxiety and 
arousal [16-18]. A recent study by Dandekar and colleagues 
used social isolation and olfactory bulbectomy models of 
depression to explore the role of CART peptides in depres-
sion [19]. They found that the social isolation-induced and 
bulbectomy-induced depression-like behaviors were reversed 
following acute or subchronic treatment with CART peptide. 
Also, an important finding was that CART peptide, given 
intracerebroventricularly (icv) by itself in normal animals, 
reduced immobility time in the forced swim test, and therefore 
CART peptide itself seems to have antidepressant properties. 
Similar results were obtained when the target of injection 
was the central nucleus of the amygdala.  
  Stress and depression are thought to be linked. The hypo-
thalamic-pituitary-adrenal (HPA) axis play a role in anxiety 
and depression [20]. During stress, the HPA-axis is activated 
and corticotrophin releasing factor (CRF) is released to 
stimulate the release of adrenocorticotropin hormone 
(ACTH) from the anterior pituitary, which in turn stimulates 
the release of glucocorticoids from the adrenal glands. Stress 
regulates CART expression in parts of the hypothalamus [21,  
22], perhaps through several mechanisms. CRF regulates 
CART peptide release in the HPA-axis [23], and vice versa 
[24]. Approximately 60% of CART varicosities in the 
hypothalamic paraventricular nucleus (PVN) were shown to 
thalamic paraventricular nucleus (PVN) were shown to be in 
juxtaposition to CRF-containing neurons [25], and CART 
peptides affect the HPA axis through CRF activation [24]. 
Moreover, glucocorticoids regulate CART levels in plasma 
[26] and in the brain [27], and CART has been suggested to 
be involved in the HPA-axis stress response [28].  
  The hypothalamic-pituitary-thyroid (HPT)-axis is also 
thought to play a role in the pathophysiology of depression 
[29]. Thyrotropin-releasing hormone-(TRH) has been shown 
to have antidepressant properties [30-32], and TRH-1 and -2 
receptor deficient mice display an increased depression-like 
behavioral phenotype [33, 34]. Electroconvulsive therapy, 
which is an effective treatment of depression, increases TRH 
gene expression in the brain [35, 36], and the CART system 
regulates TRH activity [37-39]. This is supported by the ob-
servation that CART-containing neurons densely innervate, 
and are co-localized with, the majority of hypophysiotropic 
TRH neurons in the PVN [40-42]. Furthermore, CART ac-
tivity increased the mRNA and peptide levels of TRH in 
TRH-containing hypophysiotropic neurons, suggesting that 
CART peptides exerts a stimulatory effect on TRH [38]. 
Also, Stanley et al. showed that CART peptides stimulate 
the release of TRH [39] from hypothalamic explants,   
and Brunetti et al. presented data showing that CART   
and TRH systems seem to exert a synergistic effect [43]   
(in inhibiting dopamine release from the hypothalamus).   
It is therefore conceivable that CART may be exerting   
antidepressant effects partly due to its involvement in the 
regulation of TRH. 
  About 37% of CART neurons in the magnocellular PVN 
co-localize with oxytocin [44], suggesting that CART may 
regulate oxytocin activity. Indeed, Vrang et al. showed   
that CART activity stimulates oxytocin release from the   
hypothalamus [45]. Oxytocin has antidepressant properties 
and has been proposed to be involved in the mechanisms of 
action of some antidepressants [46, 47]. Oxytocin regulates 
the HPA-axis and CART-mediated regulation of oxytocin 
activity indicates that CART may exert antidepressant proper-
ties partly through this mechanism.  
  The hypothalamic-pituitary-somatotrophic (HPS) axis, 
like the HPA- and HPT- axes (discussed above) is also 
thought to be involved in the etiology of depression [48], and 
the CART system regulates the HPS axis. For example, 
CART peptide altered growth hormone (GH) release [39, 49] 
and interestingly, in the hypothalamic periventricular nucleus 
(PeV), approximately one-third of somatostatin cells were 
CART-immunoreactive [50, 51], suggesting that CART and 
somatostatin may regulate each other. Somatostatin has anti-
depressant properties [52, 53]; antidepressants alter soma-
tostatin pharmacology within the brain [54, 55], somatostatin 
mRNA is decreased in the hypothalamic PeV in a rats sub-
jected to chronic mild stress (a model of depression) [56], 
and repeated electroconvulsive therapy increases soma-
tostatin expression in the hippocampus [57]. The interaction 
between the CART system and the HPS-axis suggests that 
CART plays a role in depression.  
  Thus, CART peptides are heavily involved in hypotha-
lamic mechanisms and may exert an antidepressant action 
through these mechanisms. But CART can have antidepres-14    Current Neuropharmacology, 2011, Vol. 9, No. 1  Job et al. 
sant effects through other mechanisms and brain regions as 
well. Many antidepressants increase serotonin (5HT) which 
produces many effects some of which are antidepressant. It 
was shown that injection of CART 61-102 into the dorsal 
raphe nucleus increased 5HT efflux as determined by in vivo 
microdialysis suggesting that CART peptide may exert an 
antidepressant effect via serotonergic mechanisms [58].  
  Interestingly, a recent study showed that repeated elec-
troconvulsive shock (an effective treatment for depression in 
humans), increased CART mRNA and CART protein in the 
rat nucleus accumbens [59], a brain region involved in re-
ward. Further, it has been proposed that BDNF (brain-
derived neurotrophic factor) is required for antidepressant-
induced behavioral effects [60-62], and CART peptides have 
been shown to increase BDNF mRNA in hippocampal neu-
rons [63]. Taken together, these data suggest that CART may 
behave like an antidepressant; however, more experiments 
are necessary to determine the precise role of CART in 
modulating depression-like behaviors. . 
  There are some other interesting observations. CART 55-
102 produces arousal and antidepressant-like behavior at 
doses lower than those required for other physiologic effects. 
For example, CART peptide levels in icv injections that pro-
duce antidepressant-like effects were in the 25-100 ng range, 
while doses for anti-feeding effects are in the 1-2 ug range 
[64]. Also, CART peptide can produce anxiogenic or arousal 
effects in doses that are less than 1 ug [17]. Thus, the most 
potent effects of CART peptides may have to do with anxi-
ety and depression. 
  Another interesting observation is a connection with drug 
abuse in humans. Human drug abuse often shows a co-
occurrence with anxiety and depression (see [65] for refer-
ences). It is interesting that CART peptides represents mole-
cules that affect both drug intake [4] and depression   
and anxiety, as summarized above. This is not to suggest   
that the co-occurrence of drug use and mood disorders is   
due solely to a problem with CART peptides, but the CART 
system is likely to be an important factor in drug abusing 
populations. 
  Data from humans and animals suggest that CART is 
associated with depression. As summarized above, there are 
several potential mechanisms by which CART may change 
behaviors and neural circuitry associated with depression . 
Thus, the CART system is a reasonable target for antidepres-
sant and anti-anxiety drug discovery [14, 66]. A more precise 
determination of the role of CART in depression will require 
a better understanding of depression itself. Also, because of 
its role in drug abuse, CART-derived medications may be 
useful in a drug abuse setting.  
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